![Chao Hong Hu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chao Hong Hu
Director/Board Member at
HUTCHMED (CHINA) LIMITED
Net worth: 66 M $ as of 2026-05-30
Profile
Chao Hong Hu was the founder of Shanghai Miracogen, Inc., founded in 2014, serving as Chairman & General Manager from 2014 to 2024.
Current jobs include Independent Non-Executive Director at BioDlink International Co., Ltd. since 2026 and Independent Non-Executive Director at HUTCHMED (China) Ltd. since 2024.
Former jobs include Co-Chief Executive Officer & Executive Director at Lepu Biopharma Co., Ltd. from 2020 to 2024, Director-Molecular Biology & Clinical Immunology at ID Biomedical Corp., Director-Bioassay Development & Process Analytics at Seagen, Inc. from 2007 to 2013, and Head-Molecular Biology & Clinical Immunology at GSK Plc from 2006 to 2007.
Education includes an undergraduate degree from Wuhan University in 1986 and a doctorate from the Chinese Academy of Sciences.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-07-10 | 121,180,106 ( 6.72% ) | 66 M $ | 2026-05-30 |
Chao Hong Hu active positions
| Companies | Position | Start |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Director/Board Member | 2024-11-20 |
| BIODLINK INTERNATIONAL COMPANY LIMITED | Director/Board Member | 2026-04-28 |
Former positions of Chao Hong Hu
| Companies | Position | End |
|---|---|---|
| LEPU BIOPHARMA CO., LTD. | Chief Executive Officer | 2024-01-30 |
Shanghai Miracogen, Inc.
 Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Chief Executive Officer | 2023-12-31 |
| SEAGEN INC. | Corporate Officer/Principal | 2013-09-30 |
| GSK PLC | Corporate Officer/Principal | 2007-04-30 |
ID Biomedical Corp.
 ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Corporate Officer/Principal | 2004-12-31 |
Training of Chao Hong Hu
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
74
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology Develops gene-based disease testing and subunit vaccines | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
HUTCHMED (China) Ltd.
 HUTCHMED (China) Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Wuhan University
 Wuhan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chinese Academy of Sciences
 Chinese Academy of Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TOT BIOPHARM International Co. Ltd.
 TOT BIOPHARM International Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets anti-tumor drugs | Health Technology |
Lepu Biopharma Co., Ltd.
 Lepu Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Engages in development, clinical research and industrialization of cancer targeted therapy drugs | Health Technology |
- Stock Market
- Insiders
- Chao Hong Hu
